MARC Research Trials
We lead pioneering clinical and observational studies aimed at understanding, diagnosing, and treating dementia-related conditions.
With over 35 years of research expertise, our team works with national and global partners to explore promising therapies for Alzheimer’s disease, Lewy body dementia, and Mild Cognitive Impairment.
READ-OUT
READ-OUT is an observational study evaluating: 1) how good blood tests for dementia are in terms of supporting a dementia diagnosis; 2) how well these tests perform in a real-world population (i.e., people from minority groups, who have significant medical conditions, are of advanced age); 3) whether the blood tests for dementia are good value for money for the NHS.
CareCoach
CareCoach is a study that aims to test the effects of using an online support package for caregivers. The package is designed to help caregivers develop knowledge, skills, and confidence to manage and support the care they provide a person living with dementia.
TopHat
TopHat is a trial that aims to determine whether Ondansetron, a drug already used in the NHS as an anti-sickness treatment, will be both effective and well tolerated as a treatment for visual hallucinations in people with Parkinson’s or Lewy Body Dementia.
MK1167-008
MK1167-008 is a placebo-controlled trial testing the safety of the investigational medication, MK-1167, and how well it may work when people take it with their current Alzheimer’s disease dementia medicine.
ReTain
ReTain is a placebo-controlled trial evaluating whether an active immunotherapy is safe and effective at slowing the onset of Alzheimer’s disease in people who are at risk.
POLARIS-AD
POLARIS-AD is a placebo-controlled trial investigating whether the drug, AR1001, may help the blood vessels in the brain work better for people with Alzheimer's disease.
EVOKE and EVOKE Plus
EVOKE and EVOKE Plus are placebo-controlled trials investigating whether the drug, Semaglutide, may help with cognition and daily functioning.
CLARITY-AD
CLARITY-AD is a placebo-controlled trial in the Open Label Extension Phase, investigating whether the drug, Lecanemab, helps slow the progression of Alzheimer’s disease.
TrailRunner
TrailRunner is a placebo-controlled trial evaluating whether the drug Remternetug is safe and effective at slowing the onset of Alzheimer’s disease in people who are at risk.
BRIC
BRIC is an observational study investigating how inflammation might play a role in cognitive problems for people with Lewy body dementia.
COBALT
COBALT is a placebo-controlled trial investigating whether Memantine improves health and functioning for people with dementia with Lewy bodies. Memantine is already licensed to help treat symptoms in Alzheimer's disease.
TRAILBLAZER5
TRAILBLAZER5 is a placebo-controlled trial investigating whether the drug, Donanemab, may help slow the progression of Alzheimer’s disease.
PEBBAL2
PEBBAL2 is an observational study investigating how the permeability of the blood brain barrier and inflammation might contribute to cognitive decline in Alzheimer's disease.
COGNIKET-MCI
COGNIKET-MCI is a placebo-controlled trial investigating whether ketones and B vitamins help cognitive function for people with Mild Cognitive Impairment.